US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emmaus Life Sciences, Inc.

0.0154

0.0000

Volume:50.00

Turnover:0.75

Market Cap:1.08M

PE:-0.14

High:0.0154

Open:0.0154

Low:0.0154

Close:0.0154

52wk High:0.0470

52wk Low:0.0080

Shares:70.20M

Float Shares:35.99M

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1141

EPS(LYR):-0.0703

ROE:-13.36%

ROA:-1.89%

PB:-0.02

PE(LYR):-0.22

Loading ...

Overview Company News Filings

BRIEF-Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech

Emmaus Life Sciences Inc - Grants Nit Exclusive License to Market, Sell and Distribute Endari in U.S. and Canada

THOMSON REUTERS

Emmaus Life Sciences Inc - Enters License and Distribution Agreement With Neoimmunetech

THOMSON REUTERS

Emmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari

Emmaus Life Sciences Swaps $3M Note for New Equity and $600K Convertible Note

Emmaus Life Sciences Director Ian Zwicker Resigns

Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025

Emmaus Life Sciences Q3 EPS USD -0.03

THOMSON REUTERS

Emmaus Life Sciences Q3 Net Income USD -2.076 Million

THOMSON REUTERS

Emmaus Life Sciences Q3 Operating Expenses USD 2.436 Million

THOMSON REUTERS

Press Release: Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences Reports 48% Drop in Q2 Net Revenues, $1.1M Net Loss, EPS of $0.02

Emmaus Life Sciences Q2 Gross Profit USD 2.667 Million

THOMSON REUTERS

Emmaus Life Sciences Q2 Operating Expenses USD 3.037 Million

THOMSON REUTERS

Emmaus Life Sciences Q2 Net Income USD -1.135 Million

THOMSON REUTERS

Emmaus Life Sciences Q2 Income From Operations USD -370 Thousand

THOMSON REUTERS

Emmaus Life Sciences Reports Quarterly Financial Results

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EMMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMMA\",,,,,undefined,":{"symbol":"EMMA","market":"US","secType":"STK","nameCN":"Emmaus Life Sciences, Inc.","latestPrice":0.015437,"timestamp":1770733800060,"preClose":0.015437,"halted":0,"volume":50,"delay":15,"changeRate":0,"floatShares":35988185,"shares":70198300,"eps":-0.114131,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-10 09:30:00 EST Delay","open":0.015437,"high":0.015437,"low":0.015437,"amount":0.75,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.114131,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":0,"adr":0,"exchange":"OTCQB","adjPreClose":0.015437,"volumeRatio":0.000611},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMMA\",,,,,undefined,":{"symbol":"EMMA","floatShares":35988185,"roa":"-1.89%","roe":"-13.36%","lyrEps":-0.070294,"volumeRatio":0.000611,"shares":70198300,"dividePrice":0,"high":0.015437,"amplitude":0,"preClose":0.015437,"low":0.015437,"week52Low":0.008,"pbRate":"-0.02","psRate":"0.09","week52High":0.047,"institutionHeld":0,"latestPrice":0.015437,"eps":-0.114131,"divideRate":0,"volume":50,"delay":15,"ttmEps":-0.114131,"open":0.015437,"prevYearClose":0.013,"prevWeekClose":0.0139,"prevMonthClose":0.0139,"prevQuarterClose":0.013,"fiveDayClose":0.0139,"twentyDayClose":0.0134,"sixtyDayClose":0.0091},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-19","symbol":"EMMA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731992400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-11-14","symbol":"EMMA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1668402000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-08-15","symbol":"EMMA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1660536000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2019-11-12","symbol":"EMMA","fiscalQuarterEnding":null,"expectedEps":-1.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1573534800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2019-08-12","symbol":"EMMA","fiscalQuarterEnding":"2019/06","expectedEps":-1.56,"name":null,"time":"","type":"earning","dateTimestamp":1565582400000,"reportTimeType":"","actualEps":-1.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMMA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMMA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2595661748","title":"BRIEF-Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech","url":"https://stock-news.laohu8.com/highlight/detail?id=2595661748","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595661748?lang=en_us&edition=fundamental","pubTime":"2025-12-31 06:24","pubTimestamp":1767133463,"startTime":"0","endTime":"0","summary":"BRIEF-Emmaus Life Sciences Enters License And Distribution Agreement With NeoimmunetechDec 30 (Reuters) - Neoimmunetech Inc 950220.KQ:EMMAUS LIFE SCIENCES INC - ENTERS LICENSE AND DISTRIBUTION AGREEME","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y00K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMMA","BK4007"],"gpt_icon":0},{"id":"2595103957","title":"Emmaus Life Sciences Inc - Grants Nit Exclusive License to Market, Sell and Distribute Endari in U.S. and Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2595103957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595103957?lang=en_us&edition=fundamental","pubTime":"2025-12-31 05:30","pubTimestamp":1767130237,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y00K0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMMA","BK4007"],"gpt_icon":0},{"id":"2595103847","title":"Emmaus Life Sciences Inc - Enters License and Distribution Agreement With Neoimmunetech","url":"https://stock-news.laohu8.com/highlight/detail?id=2595103847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595103847?lang=en_us&edition=fundamental","pubTime":"2025-12-31 05:30","pubTimestamp":1767130237,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y00K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMMA","BK4007"],"gpt_icon":0},{"id":"2595471036","title":"Emmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari","url":"https://stock-news.laohu8.com/highlight/detail?id=2595471036","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595471036?lang=en_us&edition=fundamental","pubTime":"2025-12-31 05:30","pubTimestamp":1767130216,"startTime":"0","endTime":"0","summary":"Emmaus Life Sciences Inc. announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under the terms of the agreement, Emmaus has granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari  and any generic equivalents for the treatment of sickle cell disease in the U.S., its territories, and Canada. The agreement includes an upfront payment to Emmaus and a royalty on product sales by NeoImmuneTech. The effective date of the agreement is contingent upon NeoImmuneTech obtaining the necessary regulatory approvals and licensing to sell and distribute the products, as well as the fulfillment of other specified conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL3ynWqd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EMMA"],"gpt_icon":0},{"id":"2593458346","title":"Emmaus Life Sciences Swaps $3M Note for New Equity and $600K Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458346","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458346?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:02","pubTimestamp":1766437354,"startTime":"0","endTime":"0","summary":"Emmaus Life Sciences Inc. has entered into an Exchange Agreement with a single individual, under which the company will issue 6,332,692 shares of common stock and a new $600,000 convertible promissory note. This transaction is in exchange for the surrender and cancellation of a previous $3,000,000 convertible promissory note. The new note bears interest at 10% per annum, payable semi-annually, and is convertible into common stock at an initial price of $0.01 per share, subject to adjustment. The principal amount of the new note is due on demand. No additional consideration was paid in connection with this exchange. The securities will be issued without registration under the Securities Act, relying on an exemption from registration.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDLc4ZKcK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EMMA"],"gpt_icon":0},{"id":"2592197463","title":"Emmaus Life Sciences Director Ian Zwicker Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2592197463","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592197463?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:06","pubTimestamp":1766178388,"startTime":"0","endTime":"0","summary":"Emmaus Life Sciences Inc. announced that Ian Zwicker has resigned as a director, effective December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL5snpY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EMMA"],"gpt_icon":0},{"id":"2583568194","title":"Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583568194","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583568194?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:58","pubTimestamp":1763153891,"startTime":"0","endTime":"0","summary":"Emmaus Life Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9DzLXz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EMMA"],"gpt_icon":0},{"id":"2583990681","title":"Emmaus Life Sciences Q3 EPS USD -0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2583990681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583990681?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:57","pubTimestamp":1763153871,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX5240BF:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EMMA"],"gpt_icon":0},{"id":"2583819186","title":"Emmaus Life Sciences Q3 Net Income USD -2.076 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583819186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583819186?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:57","pubTimestamp":1763153871,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX5240BF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMMA","BK4007"],"gpt_icon":0},{"id":"2583681911","title":"Emmaus Life Sciences Q3 Operating Expenses USD 2.436 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681911?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:57","pubTimestamp":1763153871,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX5240BF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMMA","BK4007"],"gpt_icon":0},{"id":"2583917681","title":"Press Release: Emmaus Life Sciences Reports Quarterly Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583917681","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583917681?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:57","pubTimestamp":1763153820,"startTime":"0","endTime":"0","summary":"\"We experienced a 38% decline in net revenues for the three months ended September 30, 2025 as compared to the same period in 2024 due to ongoing competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa, or MENA, region,\" commented Willis Lee, Chairman and Chief Executive Officer of Emmaus. \"We realized income from operations of $0.7 million compared to $0.8 million in the prior year, partially offset by a 43% reduction in operating expenses,\" he added.Net Revenues. Net revenues for the three months ended September 30, 2025 were $3.4 million, compared to $5.5 million in the same period in 2024. The decrease was due to a decrease in U.S. sales which management attributes to competition from the generic version of L-Glutamine introduced in the market in mid-2024 and a decrease of sales in the MENA region, which management attributes to the timing of sales in the region.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","SCD","EMMA","BK4232","BK4007","R"],"gpt_icon":0},{"id":"2559969467","title":"Emmaus Life Sciences Reports 48% Drop in Q2 Net Revenues, $1.1M Net Loss, EPS of $0.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2559969467","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559969467?lang=en_us&edition=fundamental","pubTime":"2025-08-15 03:14","pubTimestamp":1755198847,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire  on August 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDLc0VL0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMMA"],"gpt_icon":0},{"id":"2559969463","title":"Emmaus Life Sciences Q2 Gross Profit USD 2.667 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2559969463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559969463?lang=en_us&edition=fundamental","pubTime":"2025-08-15 03:13","pubTimestamp":1755198830,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX873C71:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMMA","BK4007"],"gpt_icon":0},{"id":"2559969450","title":"Emmaus Life Sciences Q2 Operating Expenses USD 3.037 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2559969450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559969450?lang=en_us&edition=fundamental","pubTime":"2025-08-15 03:13","pubTimestamp":1755198830,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX873C71:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EMMA"],"gpt_icon":0},{"id":"2559896946","title":"Emmaus Life Sciences Q2 Net Income USD -1.135 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2559896946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559896946?lang=en_us&edition=fundamental","pubTime":"2025-08-15 03:13","pubTimestamp":1755198830,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX873C71:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EMMA"],"gpt_icon":0},{"id":"2559454969","title":"Emmaus Life Sciences Q2 Income From Operations USD -370 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2559454969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559454969?lang=en_us&edition=fundamental","pubTime":"2025-08-15 03:13","pubTimestamp":1755198830,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX873C71:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMMA","BK4007"],"gpt_icon":0},{"id":"2559969457","title":"Emmaus Life Sciences Reports Quarterly Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2559969457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559969457?lang=en_us&edition=fundamental","pubTime":"2025-08-15 03:13","pubTimestamp":1755198829,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA2ZY5TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EMMA"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}